Anthony Mauro Net Worth

The estimated Net Worth of Anthony Mauro is at least $9.72 Million dollars as of 13 March 2024. Mr Mauro owns over 250,000 units of Viatris stock worth over $2,756,119 and over the last 10 years he sold VTRS stock worth over $3,422,500. In addition, he makes $3,544,610 as Pres of Developed Markets at Viatris.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr Mauro VTRS stock SEC Form 4 insiders trading

Mr has made over 16 trades of the Viatris stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 250,000 units of VTRS stock worth $3,022,500 on 13 March 2024.

The largest trade he's ever made was exercising 270,249 units of Viatris stock on 2 March 2024 worth over $3,064,624. On average, Mr trades about 43,849 units every 128 days since 2015. As of 13 March 2024 he still owns at least 243,044 units of Viatris stock.

You can see the complete history of Mr Mauro stock trades at the bottom of the page.

Mr. Anthony Mauro biography

Anthony Mauro is the Pres of Developed Markets at Viatris.

What is the salary of Mr Mauro?

As the Pres of Developed Markets of Viatris, the total compensation of Mr Mauro at Viatris is $3,544,610. There are 2 executives at Viatris getting paid more, with Robert J. Coury having the highest compensation of $16,605,440.

How old is Mr Mauro?

Mr Mauro is 48, he's been the Pres of Developed Markets of Viatris since . There are 8 older and 5 younger executives at Viatris. The oldest executive at Viatris Inc. is Sanjeev Narula, 60, who is the Chief Financial Officer.

What's Mr Mauro's mailing address?

Anthony's mailing address filed with the SEC is 1000 MYLAN BOULEVARD, , CANONSBURG, PA, 15317.

Insiders trading at Viatris

Over the last 4 years, insiders at Viatris have traded over $17,988,707 worth of Viatris stock and bought 85,788 units worth $1,086,462 . The most active insiders traders include Ian C Read, James M Kilts, and Robert J Coury. On average, Viatris executives and independent directors trade stock every 13 days with the average trade being worth of $708,761. The most recent stock trade was executed by Rajiv Malik on 28 August 2024, trading 100,000 units of VTRS stock currently worth $1,195,000.

What does Viatris do?

Viatris Inc., a healthcare company, develops, licenses, manufactures, markets, and distributes brand and generic drugs, complex generics, biosimilars, and active pharmaceutical ingredients (APIs) worldwide. The company operates through Developed Markets, Greater China, JANZ, and Emerging Markets segments. It offers drugs in various therapeutic areas, including infectious diseases and non-communicable diseases; HIV/AIDS; and oncology, immunology, endocrinology, ophthalmology, and dermatology, as well as antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas. The company provides medicines, such as Wixela, Inhub, ADVAIR DISKUS, glatiramer acetate injection, Copaxone, and over the counter products in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions; and support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. The company sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, and EpiPen auto-injector; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; Trastuzumab injection; and Celebrex and anti-retrovirals names, as well as offers biosimilars franchises, including Fulphila, Ogivri, and Hulio. Viatris Inc. has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. The company was founded in 1961 and is based in Canonsburg, Pennsylvania.

Complete history of Mr Mauro stock trades at Mylan NV and Viatris

Viatris executives and stock owners

Viatris executives and other stock owners filed with the SEC include:

• Robert J. Coury,
  Exec. Chairman
• Rajiv Malik,
  Pres & Exec. Director
• Anthony Mauro,
  Pres of Developed Markets
• Michael Goettler,
  CEO & Exec. Director
• Sanjeev Narula,
  Chief Financial Officer
• Klimentiy Vakhrameev,
  Director
• Aleksey Sapronov,
  Director
• Anton Checha,
  Director
• Ivan Myasoedov,
  Chief Accountant
• Mikhail Churkin,
  General Director (CEO), Director
• Marina Filippenko,
  Chairman of the Board
• Melissa Trombetta,
  Head of Global Investor Relations
• David Bayles,
  Chief Compliance Officer
• Brian S. Roman,
  Global Gen. Counsel
• Ramkumar Rayapureddy,
  Chief Information Officer
• Paul B. Campbell,
  Chief Accounting Officer, Sr. VP & Corp. Controller
• Sanjeev Kumar Sethi,
  Chief Operating Officer
• Richard A Mark,
  
• Goff Corinne Le,
  Chief Commercial Officer
• Coelho Rogerio Vivaldi,
  
• Elisha W Finney,
  
• James M Kilts,
  
• Brian Roman,
  Chief Legal Officer
• Leo Frans Groothuis,
  
• Rajiv Malik,
  
• Bryan Supran,
  Director
• Douglas E. Giordano,
  Director
• Dillon Jo Ellen Lyons,
  
• Margaret M. Madden,
  Director
• Inc Pfizer,
  10% owner
• Neil F Dimick,
  Director
• Melina E Higgins,
  
• Xiangyang (Sean) Ni,
  President, Greater China
• Sanjeev Narula,
  Chief Financial Officer
• Robert J Coury,
  Executive Chairman
• Ian C Read,
  Director
• Der Meer Mohr Pauline Van,
  Director
• Paul Campbell,
  See Remarks
• Menassie Taddese,
  See Remarks
• Harry Korman,
  
• Michael Goettler,
  Chief Executive Officer
• Scott Andrew Smith,
  Chief Executive Officer
• Andrew Cuneo,
  See Remarks
• Theodora Mistras,
  Chief Financial Officer
• Mark W Parrish,
  
• Anthony Mauro,
  See Remarks
• W Don Cornwell,